Pharma Research

Basel, Switzerland

Pharma Research

Basel, Switzerland
SEARCH FILTERS
Time filter
Source Type

CrowdReviews Partnered with Madridge Publishers to Announce: International Pharma Conference and Expo Pharma-2017 aims to discover advances, practical experiences and innovative ideas on issues related to pharma industry, pharmacology and pharmaceutical sciences as well as a breadth of other topics Pharma-2017 invites the contributions related to Pharma. Submit your work on these broad themes (or) any other topics related to Pharma. Abstracts of all the pharma related interest areas are accepted, but are not limited to the following conference themes. Pharma-2017 Conference Themes: · Pharma applications in Microbiology and Biotechnology · Pharmaceutical Chemistry · Biopharmaceutics and Pharmaceutics · Pharmacy Practice · Pharmacology · Drug Discovery and Development · Protein-Protein Interactions as Drug Targets · Pharmaceutical Nanotechnology · Drug Regulatory Affairs · Clinical Pharmacy · Pharmaceutical Technology · Pharmaceutics · Pharmacognosy and Phytochemistry For Abstract submission please see: http://pharma.madridge.com/abstract-submission.php Pharma-2017 Organizing Committee: · Bülent Gumusel, Hacettepe University, Turkey · Abubaker Ibrahim Mohamed Saeed Elbur, Taif University, Saudi Arabia. · Francesco Maione, University of Naples Federico II, Italy. · Gavin Andrews, Queens University Belfast, United kingdom. · Gian Carlo Tenore, University of Naples "Federico II," Italy. · Lisa E. Davis, University of Arizona, USA. · Majed Isa, Taif University, Saudi Arabia. · Mirza R. Baig, Dubai Pharmacy College, UAE. · Majed AIRobaian, Taif University, Saudi Arabia. · Prakash Kinthada, Sri Vidyanikethan Engineering College, India. · Tahani Alrabeni, Riyadh Colleges, Saudi Arabia. Pharma-2017 organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in Pharma Research. Pharma-2017 welcomes Sponsorship and Exhibitions from the Companies and Organizations who wish to showcase their products at this exciting event. Register for the conference and book your slots at: http://pharma.madridge.com/register.php Contact person: Narasimha Chary pharma@madridge.com pharma@madrodge.net Naples, FL, May 22, 2017 --( PR.com )-- International Pharma Conference and Expo is going to be held during November 20-22, 2017 at Dubai, UAE.Pharma-2017 aims to discover advances, practical experiences and innovative ideas on issues related to pharma industry, pharmacology and pharmaceutical sciences as well as a breadth of other topicsPharma-2017 invites the contributions related to Pharma. Submit your work on these broad themes (or) any other topics related to Pharma. Abstracts of all the pharma related interest areas are accepted, but are not limited to the following conference themes.Pharma-2017 Conference Themes:· Pharma applications in Microbiology and Biotechnology· Pharmaceutical Chemistry· Biopharmaceutics and Pharmaceutics· Pharmacy Practice· Pharmacology· Drug Discovery and Development· Protein-Protein Interactions as Drug Targets· Pharmaceutical Nanotechnology· Drug Regulatory Affairs· Clinical Pharmacy· Pharmaceutical Technology· Pharmaceutics· Pharmacognosy and PhytochemistryFor Abstract submission please see:Pharma-2017 Organizing Committee:· Bülent Gumusel, Hacettepe University, Turkey· Abubaker Ibrahim Mohamed Saeed Elbur, Taif University, Saudi Arabia.· Francesco Maione, University of Naples Federico II, Italy.· Gavin Andrews, Queens University Belfast, United kingdom.· Gian Carlo Tenore, University of Naples "Federico II," Italy.· Lisa E. Davis, University of Arizona, USA.· Majed Isa, Taif University, Saudi Arabia.· Mirza R. Baig, Dubai Pharmacy College, UAE.· Majed AIRobaian, Taif University, Saudi Arabia.· Prakash Kinthada, Sri Vidyanikethan Engineering College, India.· Tahani Alrabeni, Riyadh Colleges, Saudi Arabia.Pharma-2017 organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in Pharma Research. Pharma-2017 welcomes Sponsorship and Exhibitions from the Companies and Organizations who wish to showcase their products at this exciting event.Register for the conference and book your slots at:Contact person:Narasimha Chary


BALERNA, Switzerland--(BUSINESS WIRE)--APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products, is proud to announce the reinforcement of its consumer products portfolio with SwitzAge®, an innovative range of nutraceuticals, 100% Swiss made, specifically created to meet adult people well-being needs. Life expectancy has been globally growing in the last decades thanks to the overall improvement of life quality standards and the so-called Generation X is having a transformative impact on society. By 2050, the number of over 50s worldwide is projected to double to nearly 3.2 billion people. These consumers are transforming what it means to be older in terms of lifestyle and aim for an overall improvement of their vitality, thus being more conscious of their diet and combing it with the consumption of specific food supplements. Asia-Pacific countries, in particular, where adult people account for almost 30% of the population, seem to drive the growth of the global food supplements market with an expected CAGR of 9.1% in the next five years, thus generating nearly half of the whole market, estimated around 84 USD billion, by 2020. The SwitzAge® project has been specifically designed to match the increasing demand for high-quality food supplements tailored on adult people health needs. SwitzAge® was inspired from a holistic approach focused on the specific physiological needs of man and lady for a balanced well-being of body and mind along the ageing natural course. Each SwitzAge® product is the result of the Swiss high-quality pharmaceutical research applied to healthy ageing. In particular, products formulations contain a balanced mix of active ingredients - vitamins, minerals and functional extracts, accurately selected and controlled along the production process according to highest Swiss quality standards. On the other side, SwitzAge® formulations are compliant with European, Swiss and current Chinese food supplement regulations, thus ensuring a favourable tolerability profile. Moreover, they are lactose, sugar and gluten free and they all come in user-friendly pharmaceutical forms (mono-dose effervescent powder, chewable tablets and soft-gel capsules) for an easier administration, whilst offering the appropriate daily dosage in compliance with European and Swiss NRV recommendations. SwitzAge® product line is currently made of 8 food supplements, that provide the right answers for body and mind enhancement, by improving physical energy extent as well as the overall balance in terms of memory, concentration and sleep quality, along with a proper differentiation per gender. Among the others, the range spans solutions for cardiovascular system efficiency and genitourinary well-being, for men, as well as for menopause hormonal swing regulation and skin anti-ageing for ladies. "We are very proud - said Paolo Galfetti, CEO and Co-Founder of APR - to offer this new business opportunity to potential partners who are ready to exploit the increasing growth of the food supplement market addressed to adult and mature people needs. Seizing the global trend towards healthy ageing, SwitzAge® is the first range of scientific proven solutions which aims at enhancing adult and mature people quality of life, enabling their physical, social and mental well-being.” APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For press releases and other company information, please visit: www.apr.ch or www.switzage.ch/en


BALERNA, Switzerland--(BUSINESS WIRE)--APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, announces today the preliminary results of a global market research project commissioned to IDR Medical, a leading international healthcare market research organization. The study gathered insights from over 100 interviews conducted in seven countries: U.S.A., U.K., Germany, France, Italy, Spain and Portugal. Main objective of the research was to validate the most relevant drivers for decisions and unmet needs of Phenylketonuria (PKU) patients, families and healthcare professionals. The results highlighted that dietary compliance is still a key issue in PKU management. The survey showed that physicians and dieticians’ concerns mainly focus on securing and supporting patient adherence to the prescribed dietary regimen, thus achieving a balance between nutritional intake and metabolic management and allowing an appropriate control of PHE levels. Most of the patients and HCPs reported that palatability (taste and odor) of aminoacids (AA) formulations still represents a significant obstacle to obtain better and long-term patient compliance to the dietary treatment as well as it has a significant impact on quality of life. “As part of our patient-centric approach, we start all our research and development projects deeply analysing if there are patients and/or healthcare professionals’ needs still unmet. – states Paolo Galfetti, CEO of Applied Pharma Research – IDR Medical market research confirmed APR’s intuitions and perspectives in the development of a new medical food designed to obtain, through the application of an innovative pharmaceutical technology, patients’ acceptance of daily dietary restrictions. We are confident that APR’s innovative Medical Food will make the difference in PKU patients’ life, enabling them to exploit their current and future potential.” PKU is a rare, genetic, recessive metabolic disorder affecting about 50’000 people worldwide (on average 1:10’000 new born) and characterized by the lack or the malfunctioning of a liver enzyme needed to process phenylalanine (“PHE”), an essential amino acid. There is no cure for PKU, it can only be treated through a stringent, life-long, low-protein (low-PHE) dietetic treatment combined with a daily assumption of Medical Foods which provide PHE-free amino acids and other important micronutrients, needed due to the dietary restrictions of PKU patients. The ideal management of a PKU dietary regimen aims at maintaining the best possible balance between nutritional intake and metabolic management, assuring compliance through a strict low protein diet and an AA mix supplementation. APR developed a patented new technology to provide PKU patients with an innovative PHE-free Medical Food, engineered to allow a physiological absorption of amino acids, mimicking that of dietary proteins. This advanced formulation, has the potential to contribute to the maintenance of PHE levels within the recommended ranges, with less prominent fluctuations of PHE levels over time, thus meeting one of the most significant healthcare professionals’ concerns. The applied patented technology, on the other hand, is able to mask taste and odor of free amino acids, by creating a product that can be easily accepted by patients in order to obtain a better and lasting compliance to the dietary treatment, thus fulfilling one of the first unmet needs of PKU patients. APR will take part as sponsor in some forthcoming international events on inherited metabolic disorders. During the 13th ICIEM (International Congress of Inborn Errors of Metabolism) in Rio de Janeiro (September 5th-8th) scientific data about the patented technology at the basis of this innovation will be presented. On October, 5th-8th 2017, the 31st E.S. PKU Conference (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria Conference), which will be held in Hell (Norway) will be a great occasion to deepen APR familiarity with patients’ needs and clinicians’ expectations. About APR Applied Pharma Research s.a. APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis. For press releases and other company information visit: www.apr.ch


News Article | August 1, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2017. Results and business highlights for the quarter included: “ Foundation Medicine delivered a strong second quarter, highlighted by record clinical volume and total revenue, increased adoption of our molecular information solutions by both clinicians and biopharma partners, and importantly, improved cancer care for the patients we serve,” said Troy Cox, chief executive officer of Foundation Medicine. “ In addition, we advanced the parallel review with FDA and CMS for FoundationOne CDx with the submission of our final module to the FDA in June, a significant milestone in the process. If approved, FoundationOne CDx would become the first pan-cancer universal companion diagnostic, a highly differentiated and valuable solution for patients, oncologists and biopharma partners.” Foundation Medicine reported total revenue of $35.0 million in the second quarter of 2017, compared to $28.2 million in the second quarter of 2016. Revenue from biopharmaceutical customers was $22.1 million in the second quarter of 2017, compared to $18.9 million in the second quarter of 2016. The results of 4,762 tests were reported to biopharmaceutical customers in this year’s second quarter. Revenue from clinical testing in the second quarter of 2017 was $12.9 million, compared to $9.4 million in the second quarter of 2016. The company reported 15,924 tests to clinicians in the second quarter of 2017, a 55% increase from the same quarter last year. This number includes 12,442 FoundationOne® tests, 1,608 FoundationOne® Heme tests, 1,594 FoundationACT® tests, and 280 FoundationFocus™ CDx tests. Total operating expenses for the second quarter of 2017 were approximately $57.7 million, compared with $45.5 million for the second quarter of 2016. The increase in operating expenses was partially driven by investments in the company’s universal companion diagnostic assay, certain non-recurring cash and non-cash expenses, and investments in the company’s technology infrastructure. Net loss was approximately $44.3 million in the second quarter of 2017, or a $1.24 loss per share. At June 30, 2017, the company held approximately $71.5 million in cash, cash equivalents and marketable securities. The company will now be reporting revenue in two components: Molecular Information Services and Pharma Research and Development Services. Molecular Information Services is revenue derived from commercially available platforms and services such as sample profiling, data access and SmartTrials, and includes revenue from both clinical and biopharma customers. Pharma Research and Development Services is revenue derived from work funded primarily by biopharma partners to develop new assays and other services. This new disclosure is intended to provide additional information related to the revenue and cost of revenue specifically related to the company’s commercially available platforms and services. During the second quarter, Molecular Information Services revenue was $30.3 million, including $12.9 million in revenue generated from our clinical customers, and $17.4 million in revenue generated from our biopharma customers. Pharma Research and Development Services revenue was $4.7 million. On July 31st, Foundation Medicine entered into an agreement to expand its credit facility with Roche Finance from $100 million to $200 million. Any outstanding balance of the credit facility will convert to a term loan payable over a five-year period beginning on February 2, 2021. No funds were drawn under the credit facility at the time of the expansion. The company intends to use the proceeds to further fund product development, commercialization, corporate development initiatives and working capital. Foundation Medicine’s business and financial outlook for 2017 is the following: The company will conduct a conference call today, Tuesday, August 1st at 4:30 p.m. Eastern Time to discuss its financial performance for the 2017 second quarter and other business activities, including matters related to future performance. To access the conference call via phone, dial 1-877-270-2148 from the United States or dial 1-412-902-6510 internationally. Dial in approximately ten minutes prior to the start of the call. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at investors.foundationmedicine.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website for two weeks following the call. About Foundation Medicine Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG). Foundation Medicine®, FoundationOne® and FoundationACT® are registered trademarks, and FoundationOne CDx™ and FoundationFocus™ are trademarks, of Foundation Medicine, Inc. Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the value of the company’s business; the benefits of our products to physicians, biopharmaceutical companies, payers and patients in the treatment of cancer and personalized cancer care; the company’s financial and operational forecasts, including projections regarding the generation of revenue, the number of tests to be conducted, the incurrence of operating expenses, the timing of product development, and the expansion of reimbursement progress, including any changes to any earlier guidance; the benefits provided by a FDA-approved and CMS-covered FoundationOne CDx and progress with the Parallel Review process with FDA and CMS; the scope and timing of any approval of our universal companion diagnostic assay as a medical device by the FDA and any coverage decision by CMS; strategies for achieving Medicare coverage decisions at the local or national level and new and expanded coverage from third-party payers; and use of any funds from its credit facility. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the FDA does not approve our universal companion diagnostic assay as a medical device or that CMS does not decide to offer our universal companion diagnostic assay as a covered benefit under Medicare; the FDA or CMS is delayed in the completion of the Parallel Review process; the company's new facilities in North Carolina and Germany do not facilitate the company's ability to achieve it business objectives; the company's distribution partner outside the United States is not able to achieve market penetration in new and existing markets as quickly or as extensively as projected; Foundation Medicine's relationships with third-party or government payers do not increase or expand; Foundation Medicine is unable to sustain or grow relationships with biopharmaceutical partners; the company's revenue, test or operating expense projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the company's expectations and beliefs regarding the future conduct and growth of the company's business are inaccurate; Foundation Medicine is unable to achieve profitability, to compete successfully, to manage its growth, or to develop its molecular information platform; and the risks described under the caption “Risk Factors” in Foundation Medicine’s Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.


CrowdReviews.com Partnered with Madridge Publishers to Announce: The International Pharma Conference and Expo Pharma-2018 aims to discover advances, practical experiences and innovative ideas on issues related to the pharma industry, pharmacology and pharmaceutical sciences as well as a breadth of other topics. Pharma-2018 invites the contributions related to Pharma. Submit your work in these broad themes (or) any other topics related to Pharma. Abstracts of all the pharma related interest areas are accepted, but are not limited to the following conference themes. Pharma-2018 Conference Themes: · Pharma applications in Microbiology and Biotechnology · Pharmaceutical Chemistry · Biopharmaceutics and Pharmaceutics · Pharmacy Practice · Pharmacology · Drug Discovery and Development · Protein-Protein Interactions as Drug Targets · Pharmaceutical Nanotechnology · Drug Regulatory Affairs · Clinical Pharmacy · Pharmaceutical Technology · Pharmaceutics · Pharmacognosy and Phytochemistry For Abstract submission please see: http://pharma.madridge.com/abstract-submission.php Pharma-2018 Organizing Committee: · Bülent Gumusel Hacettepe University, Turkey · Abubaker Ibrahim Mohamed Saeed Elbur Taif University, Saudi Arabia. · Francesco Maione University of Naples Federico II, Italy. · Gavin Andrews Queens University Belfast, United kingdom. · Gian Carlo Tenore University of Naples "Federico II," Italy. · Lisa E.Davis University of Arizona, USA. · Majed Isa Taif University, Saudi Arabia. · Mirza R. Baig Dubai Pharmacy College, UAE. · Majed AIRobaian Taif University, Saudi Arabia. · Prakash Kinthada Sri Vidyanikethan Engineering college, India. · Tahani Alrabeni Riyadh Colleges, Saudi Arabia. Pharma-2018 organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in Pharma Research. Pharma-2017 welcomes Sponsorship and Exhibitions from the Companies and Organizations who wish to showcase their products at this exciting event. Register for the conference and book your slots at: http://pharma.madridge.com/register.php Contact person: Narasimha Chary pharma@madridge.com pharma@madrodge.net Naples, FL, August 03, 2017 --( PR.com )-- International Pharma Conference and Expo is going to be held during May 2-4, 2018 in Rome, Italy.Pharma-2018 aims to discover advances, practical experiences and innovative ideas on issues related to the pharma industry, pharmacology and pharmaceutical sciences as well as a breadth of other topics.Pharma-2018 invites the contributions related to Pharma. Submit your work in these broad themes (or) any other topics related to Pharma. Abstracts of all the pharma related interest areas are accepted, but are not limited to the following conference themes.Pharma-2018 Conference Themes:· Pharma applications in Microbiology and Biotechnology· Pharmaceutical Chemistry· Biopharmaceutics and Pharmaceutics· Pharmacy Practice· Pharmacology· Drug Discovery and Development· Protein-Protein Interactions as Drug Targets· Pharmaceutical Nanotechnology· Drug Regulatory Affairs· Clinical Pharmacy· Pharmaceutical Technology· Pharmaceutics· Pharmacognosy and PhytochemistryFor Abstract submission please see:Pharma-2018 Organizing Committee:· Bülent Gumusel Hacettepe University, Turkey· Abubaker Ibrahim Mohamed Saeed Elbur Taif University, Saudi Arabia.· Francesco Maione University of Naples Federico II, Italy.· Gavin Andrews Queens University Belfast, United kingdom.· Gian Carlo Tenore University of Naples "Federico II," Italy.· Lisa E.Davis University of Arizona, USA.· Majed Isa Taif University, Saudi Arabia.· Mirza R. Baig Dubai Pharmacy College, UAE.· Majed AIRobaian Taif University, Saudi Arabia.· Prakash Kinthada Sri Vidyanikethan Engineering college, India.· Tahani Alrabeni Riyadh Colleges, Saudi Arabia.Pharma-2018 organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in Pharma Research. Pharma-2017 welcomes Sponsorship and Exhibitions from the Companies and Organizations who wish to showcase their products at this exciting event.Register for the conference and book your slots at:Contact person:Narasimha Chary


BUCCAL Drug Delivery Systems Market analysis is provided for global market including development trends by regions, competitive analysis of the BUCCAL Drug Delivery Systems market. BUCCAL Drug Delivery Systems Industry report focuses on the major drivers and restraints for the key players. “BUCCAL Drug Delivery Systems: Opportunities and Challenges in Buccal, Sublingual Films, Tablets & Sprays - Detailed Analysis on Technologies and Pipeline Development” report speaks about the manufacturing process. The process is analysed thoroughly with respect four points Manufacturers, regional analysis, Segment by Type and Segment by Applications and the actual process of whole BUCCAL Drug Delivery Systems industry. Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for controlled drug delivery for extended periods of time. The mucosa is well supplied with both vascular and lymphatic drainage and first-pass metabolism in the liver and pre-systemic elimination in the gastrointestinal tract are avoided. The area is well suited for a retentive device and appears to be acceptable to the patient. With the right dosage form design and formulation, the permeability and the local environment of the mucosa can be controlled and manipulated in order to accommodate drug permeation. Buccal drug delivery is a promising area for continued research with the aim of systemic delivery of orally inefficient drugs as well as a feasible and attractive alternative for non-invasive delivery of potent peptide and protein drug molecules. In 2014, sales of Suboxone sublingual film totalled approximately $1.3 billion in the U.S. while the total market grew to more than $1.7 billion, driven by a 11 percent increase in prescriptions. In 2014, Bunavail buccal film has received US approval which has similar bioavailability of suboxone with half of the dose of buprenorphine. Global pharma companies such as Biodelivery Sciences, Bioalliance pharma (Onexo), Meda pharma, Orexo, Generex, Teijin are actively involved in developing oral mucoadhesive buccal delivery systems while sublingual technology have been used by Teva, Sun pharma, Grunenthal, Neurax, Angelini, Sandoz, Ethypharm, Arrow generics, Purdue and Actavis pharma. Sublingual spray technology have been employed by the companies such as Insys therapeutics, Perrigo, Mist pharm, Regency, Novadel, Generex, GW Pharma and Pohl Boskamp in developing potential drugs for the patients. Other than drugs used for local actions (antifungal, antiviral), generally controlled substances like buprenorphine, naloxone and fentanyl are preferred to release the drug through buccal formulations. However, testosterone (striant) to treat low testosterone levels in men also approved through use of buccal system of delivery. In the US, drugs such as Isosorbide dinitarte, ergoloid delivered sublingually have been discontinued and nitroglycerin has been replaced with sublingual metered spray. Ergomar (ergotamine tartarate) marketed by Rosedale therapeutics is the only sublingual tablets available in the US market, priced $15 per pill. Subsys (fentanyl) developed by Insys therapeutics was the recent sublingual spray approved in the US for the treatment of breakthrough cancer pain. Ease of administration and better compliance offered by delivering through buccal route offers advantages for patients and physicians over other Invasive route and oral ingestion will drive the market further in positive directions going forward. Novel buccal delivery such as soluble thin films, mucoadhesive films and rapidmist spray offers newer route of delivery for the generics that has lesser patients compliances. This report will provide detailed analysis on buccal delivery systems in broader pharma market in finding companies and technologies and complexities involved in developing this unique high potential delivery system. 6. Buccal Films • Formulation aspects • Ideal Characteristic of drugs/excipients for developing Buccal delivery formulations • Manufacturing Methods o Solvent casting method o Hot-melt extrusion o Semisolid casting o Solid dispersion o Rolling • Physico-Chemical Evaluation of Buccal Films • Marketed Buccal Films • Technologies used in Buccal/Sublingual films o BEMA o PharmaFilm 8. Sublingual films/Tablets Buccal/ sublingual formulations approved in the US including generics Buccal/ sublingual formulations discontinued in the US Buccal/ sublingual formulations underdevelopment worldwide Buccal /sublingual formulations approved in Europe 9. Other technologies used in buccal delivery systems • ArisGen Pharma (ArisCrown technology) • Mystic Pharma (VersiDoser powder technology) • Uluru (OraDisc Technology) • Tesa labtec (PerioPatch) – buccal patch • Intellidrug (Intraoral drug delivery device) • Generex Pharma (RapidMist Technology) • Insys therapeutics (sublingual spray) 10. Oral Thin fast Dissolving Films (OTF) –Ideal Characteristics, Classification and Evaluation • Auxillium Pharma (PharmForm Tech) • LTS Lohmann OTF • IntelGenx OTF • Tapemark Solustrip technology • Applied Pharma Research/Tesa Labtec – RapidFilm Technology • Tesa Labtec Pharma -Mucofilm • Cynapsus Pharma – Sublingual thin film • Seoul Pharma -SmartFilm • Other patented approaches o XGel film o Soluleaves o Wafertab o Foamburst o Micap Companies Covered • Actavis • Angelini • Applied Pharma Research • Ardana Biosciences • Auxillium Pharma  • Barr • Biodelivery Sciences • Blue fish • Cynapsus Pharma • Ethypharm • Galena • Galenica • Generex • Grunenthal • Indivior • Insys • Insys Therapeutics • IntelGenx  • Intellidrug • LTS Lohmann  • Meda Pharma • MedaPharm • Mist Pharma • Mystic Pharma • Neuraxpharm • Novadel • Novel Labs • Nycomed • Onexo • Oriform • Purdue • Rosedale Therapeutics • Roxane • Sandoz • Sanofi • Snoreeze • Tapemark  • Tesa Labtec Pharma • Teva Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


GAITHERSBURG, Maryland--(BUSINESS WIRE)--La nouvelle solution de soin des plaies Nexodyn® AOS Wound Care Solution, autorisée à la vente par la FDA, commence à être disponible aux Etats-Unis, promue et commercialisée par la société pharmaceutique italienne de premier plan Angelini, dans le cadre d'un partenariat exclusif établi avec la société suisse APR Applied Pharma Research, propriétaire et développeur de la technologie brevetée exclusive TEHCLO®, pour la production de solutions acides très


GAITHERSBURG, Md.--(BUSINESS WIRE)--Die von der FDA zum Verkauf zugelassene neue Wundversorgungslösung Nexodyn® AOS ist nun in den USA erhältlich. Sie wird vom führenden italienischen Pharmazieunternehmen Angelini gefördert und vermarktet. Grundlage ist eine exklusive Partnerschaft mit dem Schweizer Unternehmen APR Applied Pharma Research, dem Eigentümer und Entwickler der proprietären patentierten Technologie TEHCLO® zur Herstellung saurer, stark oxidierender Lösungen. Dank der Formulierung hi


GAITHERSBURG, Md.--(BUSINESS WIRE)--La nueva solución Nexodyn® AOS Wound Care, autorizada para su venta por la FDA, ha comenzado a estar disponible en EE. UU., promocionada y comercializada por la empresa farmacéutica líder italiana,Angelini, como resultado de una alianza exclusiva con la empresa suiza, APR Applied Pharma Research, propietaria y desarrolladora de la tecnología propia y patentada TEHCLO®, para la producción de soluciones de soluciones ácidas superoxidantes. Gracias a su formulac


News Article | December 12, 2016
Site: www.businesswire.com

BALERNA, Switzerland--(BUSINESS WIRE)--APR Applied Pharma Research s.a. - the Swiss independent developer of science driven patented healthcare products - and MONRONE FZC Healthcare (Monrone), the middle east Outsourcing Health and Beauty business, have recently announced they have entered a partnership agreement to promote, distribute and market the Halykoo pediatric healthcare product line in Qatar, Kuwait, United Arab Emirates, Saudi Arabia, Oman, Bahrain. Halykoo is a global umbrella brand of pediatric OTC products conceived and developed by the Switzerland based company. Halykoo innovative portfolio includes 12 different products spanning four major therapeutic areas such as skin care, cough & cold, eye, ear & mouth and nutraceutical. They all rely on formulations and delivery systems specifically tailored to match babies and children different needs throughout each stage of their growth. This partnership will allow Monrone to accomplish its transition towards becoming an established pharmaceutical company within the Middle East countries offering high quality, innovative and branded products dedicated to infants and children, such as Halykoo. “We believe our partnership with APR is an opportunity to successfully gain a sizable share of the competitive paediatric healthcare market which, in the middle east region is worth up to 120 million $. We believe Halykoo provides problem solution products offering parents a simple, safe and innovative range of goods to deal with their babies healthcare issues. – comments Mohamed Samir – Market access manager, MONRONE FZC - We have worked hard to be recognized as a highly dynamic yet very caring provider in the market of OTC products: the innovative products within the Halykoo line, are able to set a new pace in the pediatric healthcare market while providing added value to our partners in full compliance with our company’s commitment for the future.” The deal between APR and MONRONE comes after previous marketing of Halykoo in Italy, Ukraine and the former Yugoslavia area, and thanks to this agreement APR will we able to introduce its brand also in the pediatric care market of many country of the Middle East, further expanding its network distribution across the world and confirming the strong appeal and distinctive positioning of Halykoo on an international scale. Paolo Galfetti, CEO and Co-Founder of APR, explained: “Providing parents worldwide with products that meet the specific needs of their children over the first six years of their lives, Halykoo line offers the unique opportunity to face the high consumer turnover given by babies ageing out of the category. We are proud to welcome MONRONE in our growing global network partners and strongly believe it will be an important partner for us as it holds the experience, the geographic reach and distribution infrastructure to best market and deliver Halykoo product range.” he added. Halykoo is a new global brand in the pediatric OTC market, conceived and developed by APR starting from an unmet demand driven insight, which aims to transform the moments of child healthcare in a time of relation (between mother and kid) peaceful, simple and safe in order to get parents’ confidence and smiling babies. Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies. Halykoo products are the perfect combination of Swiss, high-quality research combined with an extensive understanding of child and caregivers needs: as a result, each Halykoo product provides the right formula – from accurate selection of the ingredients (including natural organic certified components), to careful dosing of the ingredients and full compliance with the strictest safety standards – and the right delivery system for the right age. For more info about Halykoo, please visit: www.halykoo.com Founded in 2012, the vision of MONRONE Healthcare. MONRONE is to become a ”widely respected regional & international Healthcare company” by advancing its mission of “persisting in Nutraceutical innovation for the benefit of human beings.” It focuses on constant improving, creating products through partnership with world class R&D laboratories that match the ever-changing lifestyles and needs of people and families everywhere. To date, over 44 of the company's products have been commercializing across the Middle-east, and over 600,000 patient leveraging these products, Monrone recognized as the most highly dynamics provider of over-the-counter products in Middle-east yet nimble enough to give detailed attention to each and every one of their products .To learn more about MONRONE, please visit us http://www.monrone.org APR is an independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering value-added, R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For more info, please visit: www.apr.ch.

Loading Pharma Research collaborators
Loading Pharma Research collaborators